Effects of tadalafil once daily or on demand versus placebo on time to recovery of erectile function in patients after bilateral nerve-sparing radical prostatectomy by Ignacio Moncada et al.
1 3
World J Urol (2015) 33:1031–1038
DOI 10.1007/s00345-014-1377-3
ORIGINAL ARTICLE
Effects of tadalafil once daily or on demand versus placebo 
on time to recovery of erectile function in patients after bilateral 
nerve‑sparing radical prostatectomy
Ignacio Moncada · Fermín R. de Bethencourt · Enrique Lledó‑García · 
Javier Romero‑Otero · Carmen Turbi · Hartwig Büttner · Carsten Henneges · 
Juan I. Martinez Salamanca 
Received: 31 March 2014 / Accepted: 5 August 2014 / Published online: 26 August 2014 
© The Author(s) 2014. This article is published with open access at Springerlink.com
treatment. Secondary outcome measures included Kaplan–
Meier estimates of time to EF-recovery (IIEF-EF ≥ 22) 
during DBT (Cox proportional hazard model adjusting for 
treatment, age, and country).
Results A total of 423 patients were randomized to 
tadalafil OaD (N = 139), PRN (N = 143), and placebo 
(N = 141); 114/122/155 completed DBT. The proportion of 
patients achieving IIEF-EF ≥22 at some point during DBT 
with OaD, PRN, and placebo was 29.5, 23.9, and 18.4 %, 
respectively. DBT was too short to achieve EF-recovery 
(IIEF-EF ≥ 22) in >50 % of patients; median time to EF-
recovery was non-estimable. Time for 25 % of patients to 
achieve EF-recovery (95 % CI) was 5.8 (4.9, 9.2) months 
for OaD versus 9.0 (5.5, 9.2) and 9.3 (9.0, 9.9) months 
for PRN and placebo, respectively. Showing a significant 
overall treatment effect (p = 0.038), the probability for 
EF-recovery was significantly higher for OaD versus pla-
cebo [hazard ratio (HR); 95 % CI 1.9; 1.2, 3.1; p = 0.011], 
but not for PRN versus placebo (p = 0.140). Of 57 OaD 
patients (41.0 %) with ED improved (by ≥1 IIEF-EF sever-
ity grade) at the end of DBT, 16 (28.1 % of 57) maintained 
this improvement through DFW and 27 (47.4 %) declined 
but maintained improvement from baseline after DFW.
Conclusions Data suggest that the use of tadalafil OaD 
can significantly shorten the time to EF-recovery post-nsRP 
compared with placebo.
Keywords Nerve-sparing prostatectomy · Penile 
function · Phosphodiesterase 5 inhibitors · Prostate cancer · 
Rehabilitation · Tadalafil once a day
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Abstract 
Purpose We report time to erectile function (EF)-recov-
ery data from a multicenter, randomized, double-blind, 
double-dummy, placebo-controlled trial evaluating tadalafil 
started after bilateral nerve-sparing radical prostatectomy 
(nsRP).
Methods Patients ≤68 years were randomized post-nsRP 
1:1:1 to 9-month double-blind treatment (DBT) with tada-
lafil 5 mg once daily (OaD), 20 mg tadalafil on demand 
(“pro-re-nata”; PRN), or placebo, followed by 6-week 
drug-free washout (DFW) and 3-month open-label OaD 
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ED  Erectile dysfunction
EF  Erectile function
HR  Hazard ratio
IIEF-EF  International Index of Erectile Function-Erec-
tile Function domain score
ITT  Intent-to-treat
LSmeans  Least square means
MCID  Minimally clinically important difference
MMRM  Mixed model for repeated measures
nsRP  Nerve-sparing radical prostatectomy
OaD  Once daily
OLT  Open-label OaD treatment
PDE5  Phosphodiesterase type 5
PRN  “Pro-re-nata,” on demand
RCTs  Randomized clinical trails
REF  Residual erection function
SD  Standard deviation
Introduction
Erectile dysfunction (ED) can be a relatively common 
sequela after radical prostatectomy for localized prostate 
cancer [1–3], despite the use of nerve-sparing techniques 
(nsRP). Many men may not recover erectile function (EF) 
for more than 18 months post-nsRP [4, 5]. Rarely, time to 
EF-recovery can extend well beyond 2 years [6]. The rate 
of and time to EF-recovery post-nsRP can vary widely and 
may be influenced by a number of factors, including patient 
age, type of surgery, and treatment during the recovery 
phase [5–7].
Phosphodiesterase type 5 (PDE5)-inhibitors are gen-
erally well-tolerated and effective in the treatment of ED 
post-nsRP [1, 2, 8]. However, they are less effective in the 
post-nsRP population when compared to the general popu-
lation, and the optimal time point for starting PDE5-inhibi-
tor treatment is still undetermined [9].
To date, four randomized clinical trials (RCTs) have 
evaluated the impact of the early use of short-acting PDE5-
inhibitors on EF-recovery in men post-nsRP. Sildenafil, 
vardenafil, and avanafil have all been shown to improve 
drug-assisted EF when given on demand (“pro-re-nata,” 
PRN) [10–12]. However, EF-recovery up to 1 year post-
nsRP did not differ between sildenafil given once daily 
(OaD) or PRN [13].
For the long-acting PDE5-inhibitor tadalafil, an initial 
retrospective study in 92 patients showed that tadalafil OaD 
started early after robot-assisted laparoscopic nsRP was 
well tolerated and significantly improved EF compared to 
patients without PDE5-inhibitor treatment [14].
Montorsi et al. [15] have published a randomized, 
placebo-controlled trial evaluating the early use of tada-
lafil, given OaD or PRN, on both drug-assisted EF after 
9 months of double-blind treatment (DBT) with tadalafil 
OaD or PRN and on unassisted EF (without PDE5-inhibitor 
support) after 6 weeks of drug-free washout (DFW) in men 
who developed ED post-nsRP. Tadalafil OaD improved 
drug-assisted EF-recovery, as measured by the proportion 
of patients achieving an International Index of Erectile 
Function-Erectile Function domain score (IIEF-EF) ≥22 at 
the end of DBT, while unassisted EF-recovery after DFW 
was not improved by tadalafil OaD or PRN [15].
This paper specifically addresses the effects of tadala-
fil OaD and PRN treatment on the time to recovery of EF 
(IIEF-EF ≥ 22) during the DBT period of this trial and the 
maintenance of treatment response after DFW.
Materials and methods
Patients
Adult men aged <68 years at the time of nsRP with normal 
preoperative EF who underwent nsRP for organ-confined, 
non-metastatic prostate cancer (Gleason score ≤7, pros-
tate specific antigen <10 ng/mL) were enrolled between 
November 2009 and August 2011 in 50 centers from nine 
European countries and Canada (NCT01026818). Post-sur-
gical inclusion criteria included the development of ED, as 
measured by a patient-reported Residual Erection Function 
(REF) score of ≤3 (“penis is hard enough for penetration 
but not completely hard”). This criterion was used because 
of the limited validity of IIEF-EF domain scores for direct 
EF assessment post-nsRP [15, 16]. Detailed eligibility cri-
teria have been published [16].
Trial design
This multicenter, Phase IV, randomized, double-blind, 
3-arm, placebo-controlled parallel-group trial consisted of 
the following periods, as previously described (Supplemen-
tary Figure S1) [15]: screening (including nsRP surgery), 
9-month randomized, double-blind, double-dummy treat-
ment with 5 mg tadalafil OaD, 20 mg tadalafil PRN, or pla-
cebo (DBT); 6-week DFW; and 3-month open-label treat-
ment with 5 mg/day tadalafil OaD (OLT, all patients).
Outcome measures
IIEF‑EF scores
The primary objective was to evaluate the efficacy of tada-
lafil OaD and tadalafil PRN, compared with placebo, in 
improving unassisted EF (EF after 6 weeks of DFW), as 
measured by the proportion of patients achieving an IIEF-
EF score ≥22 at the end of DFW (primary outcome) [15]. 
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An IIEF-EF ≥22 was required at screening (after cancer 
diagnosis, ≤6 weeks pre-nsRP). This cutoff was considered 
appropriate because many men with newly diagnosed pros-
tate cancer claim to have unimpaired EF, but have IIEF-EF 
scores of 22–25 (mild ED) [15, 17]. Time to EF-recovery 
(additional secondary analysis pre-specified in the statisti-
cal analysis plan, finalized and approved before database 
lock) was defined as the time from baseline to reach an 
IIEF-EF ≥22 during DBT.
ED severity
IIEF-EF scores were categorized into the following ED 
severity categories: severe (0–10), moderate (11–16), 
mild (17–25), and normal (26–30) [18]. ED severity 
was assessed at baseline, end of DBT, and end of DFW. 
Improvement was defined as an IIEF-EF score of ≥1 cate-
gory higher than baseline (or maintaining normal EF) at the 
end of DBT. Maintenance of treatment response, assessed 
for patients who improved ≥1 category after DBT, was 
defined as either maintaining this improved category until 
the end of DFW or declining after DBT but still maintain-
ing a higher category at the end of DFW than at baseline.
Statistical analysis
The planned sample size of 412 patients was based on the 
primary outcome (proportion of patients achieving IIEF-EF 
≥22) [15]. All analyses were based on the intent-to-treat 
(ITT) population, including all randomized patients with 
baseline data and at least one post-baseline visit. Pre-spec-
ified treatment group comparisons were tadalafil OaD ver-
sus placebo and tadalafil PRN versus placebo.
The Kaplan–Meier product-limit method was used to 
estimate rates for the time to EF-recovery (IIEF-EF ≥ 22) 
including 95 % confidence intervals (CI). Only patients 
with IIEF-EF <22 at screening were included; patients not 
reaching IIEF-EF ≥22 were censored at the end of DBT. 
Hazard ratios (HRs) and p values were derived from a Cox 
proportional hazard model adjusting for treatment, age 
(<61 years vs. 61–68 years), and country.
IIEF-EF score changes from baseline were analyzed 
using a mixed model for repeated measures (MMRM) 
analysis, assuming an unstructured covariance structure 
and including visit, treatment, treatment-by-visit interac-
tion, country, age group, and baseline as fixed effects, and 
patient and error as random effects. Adjusted least square 
means (LSmeans) and 95 % CIs were calculated from 
the model. A minimally clinically important difference 
(MCID), defined as ≥4 points difference in IIEF-EF [19], 
was used to determine the average needed treatment effect 
that has clinical relevance for patients.
For p values, a 5 % level of significance was used. Data 
were analyzed using the SAS 9.2 software (SAS Institute 
Inc., Cary, USA).
Results
Patient disposition and baseline characteristics
Of 583 patients screened, 423 were randomized: 139 
(32.9 %) to tadalafil OaD, 143 (33.8 %) to tadalafil PRN, 
and 141 (33.3 %) to placebo (Supplementary Figure S2). 
Patients in the PRN group took a mean (SD) of 1.5 (0.95) 
tadalafil 20 mg tablets per week. Patient disposition, base-
line demographics, and relevant disease characteristics 
were balanced in all 3 treatment groups (Table 1) [15]. 
As per inclusion criteria, all patients had to have IIEF-EF 
≥22 pre-nsRP. Post-nsRP at baseline, 83.9 % of patients 
reported severe ED based on IIEF-EF scores (mean [stand-
ard deviation; SD] score 6.4 [5.81]) and >98 % reported an 
REF ≤3.
Time to EF-recovery during DBT
The proportion of patients achieving IIEF-EF ≥22 at any 
time point during DBT with OaD, PRN, and placebo was 
29.5, 23.9, and 18.4 %, respectively. Based on the Kaplan–
Meier analysis, 25 % of patients achieved EF-recovery 
(IIEF-EF ≥ 22) within 5.8 months for tadalafil OaD, 
9.0 months for tadalafil PRN, and 9.3 months for placebo 
(Fig. 1a). Median time to EF-recovery could not be esti-
mated as <50 % of patients achieved EF-recovery dur-
ing the 9-month DBT period (Supplementary Figure S3). 
The Cox proportional hazard model showed a significant 
overall treatment effect (p = 0.038). Patients in the tada-
lafil OaD (but not PRN) group had a significantly higher 
probability for EF-recovery versus placebo (HR [95 % CI]: 
tadalafil OaD versus placebo: 1.90 [1.16, 3.12], p = 0.011; 
tadalafil PRN versus placebo: 1.47 [0.88, 2.47], p = 0.140). 
Age group had no significant effect on time to EF-recovery 
(p = 0.223; Supplementary Figure S4).
LSmean IIEF-EF improvements
LSmean IIEF-EF improvement during DBT significantly 
exceeded the MCID (Lower 95 % CI LSmean ΔIIEF-
EF ≥ 4) at month 5 in the tadalafil OaD treatment group 
(LSmean [95 % CI]: 6.9 [5.0, 8.8]) and month 9 in the 
tadalafil PRN treatment group (6.5 [4.6, 8.5]) (Fig. 2). For 
placebo, LSmean IIEF-EF did not significantly exceed the 
MCID before month 10.5 (end of DFW: 6.0 [3.9, 8.0]). The 
treatment effect versus placebo was statistically significant 
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for tadalafil OaD only (LSmean difference [95 % CI]: 2.8 
[0.8, 4.8]; p = 0.007) at month 9.
ED severity improvement and maintenance 
of improvement
At baseline (randomization), 83.9 % of patients overall 
had severe ED (IIEF-EF 0–10; Table 1). During DBT, 
improvement in ED severity by ≥1 severity grade was 
achieved by 41.0 % of all tadalafil OaD patients, 38.7 % 
of all tadalafil PRN patients, and 22.7 % of patients on 
placebo (Fig. 2). In all groups, the majority of those 
patients who had improved during DBT maintained an 
improvement of ≥1 severity grade from baseline through 
DFW (improvement maintained, Fig. 2). For tadalafil 
OaD (Fig. 2), 43 of 57 improved patients (75.4 %) were 
still improved from baseline after DFW, including 16 
patients (28.1 %) who maintained the improvement they 
had reached at the end of DBT and 27 patients (47.4 %) 
who declined but still maintained improvement from 
baseline after DFW.
Discussion
This trial was the first RCT in patients with established ED 
post-nsRP which investigated the effect of early treatment 
with tadalafil OaD and PRN on EF-recovery. As previously 
reported, tadalafil OaD significantly improved drug-assisted 
EF-recovery, as measured by the proportion of patients 
achieving IIEF-EF ≥22 at the end of DBT (25.2 % of OaD 
patients versus 14.2 % in placebo group; p = 0.016; Sup-
plementary Figure S3). Unassisted EF-recovery after DFW 
was not improved by tadalafil OaD or PRN [15]. Here, we 
show that tadalafil OaD (but not PRN) significantly short-
ened the time to EF-recovery during DBT when compared 
with placebo: with placebo, it took 9.3 months until 25 % of 
patients had reached EF-recovery; this period was shortened 
by 3.5 months (i.e., to 5.8 months) in the tadalafil OaD treat-
ment group. An early start of penile rehabilitation does seem 
to be important; Mulhall et al. [20] showed that patients who 
started PDE5-inhibitor treatment early post-nsRP reached 
significantly higher mean IIEF-EF scores than patients who 
started later at ≥6 months post-nsRP (p < 0.0001).
Table 1  Baseline 
characteristics and status post 
nsRP
BMI body mass index, ED 
erectile dysfunction, IIEF‑
EF International Index of 
Erectile Function-Erectile 
Function, N total number of 
patients, n number of patients, 
nsRP bilateral nerve-sparing 
prostatectomy, OaD once a day, 
PRN “pro-re-nata”/on demand, 
REF residual erectile function, 
SD standard deviation
a Based on intent-to-treat 
population, excluding one 
patient from the tadalafil PRN 
group with no post-baseline 
data
b Two patients in the tadalafil 
OaD group and two patients 
in the tadalafil PRN group had 
missing values
Variable Tadalafil OaD (N = 139) Tadalafil PRN (N = 143) Placebo (N = 141)
Age (years)
Mean (SD) 58.6 (5.07) 57.5 (5.91) 57.6 (5.69)
<61 (n, %) 82 (59.0) 85 (59.4) 91 (64.5)
61–68 (n, %) 57 (41.0) 58 (40.6) 50 (35.5)
Ethnicity (n, %)
Caucasian 137 (98.6) 141 (98.6) 138 (97.9)
BMI (kg/m2)
Mean (SD) 26.6 (2.97) 26.9 (2.93) 27.1 (3.08)
IIEF‑EF
N with data 137 140 137
Mean (SD) 6.0 (5.80) 6.7 (5.57) 6.5 (6.08)
ED severity (IIEF‑EF categories) (n, %)a
Missing 2 (1.4) 2 (1.4) 4 (2.8)
Normal (26–30) 4 (2.9) 2 (1.4) 2 (1.4)
Mild (17–25) 5 (3.6) 8 (5.6) 9 (6.4)
Moderate (11–16) 9 (6.5) 10 (7.0) 11 (7.8)
Severe (0–10) 119 (85.6) 120 (84.5) 115 (81.6)
REF ≤ 3b 137 (98.6) 138 (97.2) 141 (100)
nsRP approach (n, %)
Open surgery 68 (48.9) 65 (45.5) 56 (39.7)
Conventional laparoscopy 29 (20.9) 31 (21.7) 28 (19.9)
Robot-assisted laparoscopy 31 (22.3) 41 (28.7) 44 (31.2)
Other 11 (7.9) 6 (4.2) 13 (9.2)
Total nerve‑sparing score post‑nsRP (n, %)
Perfect (2) 117 (84.2) 116 (81.1) 113 (80.1)
Not perfect (>2) 22 (15.8) 27 (18.9) 28 (19.9)
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EF-recovery rates during 9-month DBT were <50 % in 
all treatment groups, which is in line with the published 
data on natural EF-recovery post-nsRP. Without treatment, 
time to EF-recovery averages 18 months [4] and can extend 
well beyond 2 years [5, 6]. In a study by Gallina et al. [21], 
only 35.8 % of untreated patients reached EF-recovery 
(IIEF-EF ≥ 22) after an average of 26.8 months post-nsRP.
However, LSmean IIEF-EF improvement in the 
tadalafil OaD group significantly exceeded the MCID 
(ΔIIEF-EF ≥ 4 [19]) already at month 5 of DBT, as com-
pared to month 9 for tadalafil PRN; improvement with pla-
cebo did not significantly exceed the MCID before month 
10.5 (end of DFW). At the end of DBT, the treatment effect 
versus placebo was statistically significant for tadalafil 
OaD only (p = 0.007).
Chronic (daily) dosing of tadalafil, but not PRN treat-
ment, will lead to steady state PDE5-inhibition [22] which 
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Tadalafil 5mg OaD Tadalafil 20mg PRN Placebo
Washout Open-labelDouble-blind
*
* p<0.05 (TAD OaD vs. PLC, MMRM)
MCID
1 2 3 4 5 6 7 8 9 10 11 12 13
Fig. 1  EF-recovery (IIEF-EF ≥ 22) and EF category improvement 
during DBT. CI confidence interval, DBT double-blind treatment, EF 
erectile function, IIEF‑EF International Index of Erectile Function-
Erectile Function domain, LSmean least square mean, MCID minimal 
clinically important difference, MMRM mixed model for repeated 
measures, n number of events, N number of patients, n.e. not estima-
ble, n.s. not significant, OaD once a day, PLC placebo, PRN “pro-re-
nata”/on demand, TAD tadalafil, yrs years. a Event (EF-recovery) was 
defined as change in IIEF-EF from <22 at screening to ≥22. P values 
are obtained from Cox proportional hazard model including terms 
for treatment, country, and age. b p value obtained from an MMRM 
model, assuming an unstructured covariance structure, including 
terms for visit, treatment, treatment-by-visit interaction, country, age 
group, and baseline IIEF-EF score as fixed effects, and patient and 
error as random effects. Previously published in: Montorsi et al. 2014 
[15]
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of increased tissue oxygenation during the post-operative 
regenerative process. Preclinical data suggest that chronic 
low-dose administration may protect from structural 
changes of penile cavernous corpora and is associated with 
EF enhancement [23–25].
None of the other RCTs on PDE5-inhibitors post-nsRP 
has reported time to EF-recovery data based on Kaplan–
Meier analysis. However, data from 2 non-RCTs indicated 
that PDE5-inhibitor treatment may shorten time to EF-
recovery [26, 27]. Bannowsky et al. [26] reported a sig-
nificant difference in time to EF-recovery between patients 
receiving nightly low-dose sildenafil for up to 12 months 
when compared with patients receiving no treatment 
(p < 0.001). In agreement with these results, Briganti et al. 
showed that patients receiving any PDE5-inhibitor (OaD 
or PRN) achieved significantly higher 3-year EF-recovery 
rates (IIEF-EF ≥ 22) than patients receiving placebo (72 vs. 
38 %, p ≤ 0.001, Kaplan–Meier analysis). For the overall 
population studied, no significant difference was observed 
between OaD and PRN treatment. However, patients with 
an intermediate risk of ED (66–69 years or IIEF-EF 11–25, 
and Charlson Comorbidity Index ≤1), who shared key cri-
teria with our patient population of low/intermediate ED 
risk (average patient ≤61 years; IIEF-EF ≥ 22 at baseline), 
achieved significantly higher 3-year EF-recovery rates with 
OaD compared to PRN treatment (74 vs. 52 %; p = 0.02) 
[27]. As suggested by Castiglione et al. [28], the effect 
of PDE5-inhibitor treatment post-nsRP may be maximal 
in patients with intermediate ED risk. To date, trials have 
focused on populations with low ED risk [11, 13, 15].
In our trial, age group had no significant effect on the 
time to EF-recovery during DBT or on the proportion of 
patients achieving EF-recovery during DBT [15]. However, 
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Fig. 2  Improvement and maintenance of improvement from base-
line in ED severity (based on IIEF-EF categories). DBT double-blind 
treatment, DFW drug-free washout, ED erectile dysfunction, IIEF‑EF 
International Index of Erectile Function-Erectile function domain, 
OaD once a day, PLC, placebo, PRN “pro-re-nata”/on demand, N 
total number of patients, n number of patients. IIEF-EF scores defin-
ing ED severity categories: severe, 0–10; moderate, 11–16; mild, 17–
25; normal, 26–30. Improvement was defined as reporting an IIEF-
EF score of at least 1 category higher than baseline (or maintaining 
normal EF). Improvement declined was defined as reporting IIEF-EF 
scores at the end of DFW that were less than the end of the DBT but 
still at least 1 category higher than baseline. Improvement maintained 
was defined as reporting IIEF-EF scores at the end of DFW that were 
at least as high or higher than scores at the end of DBT. Improvement 
lost was defined as IIEF-EF scores that were less than or equivalent 
to ED severity at baseline. All percentage are relative to the size of 
each treatment group (“N,” provided below each bar) not relative 
to the overall population. Missing data: For 33 patients (23.7 %) in 
the tadalafil OaD group, for 27 (19.0 %) in the tadalafil PRN group, 
and for 34 (24.1 %) in the placebo group, improvement could not 
be calculated because the patient either discontinued during DBT or 
had missing IIEF-EF scores at baseline and/or month 9. For three 
patients (5.3 %) in the tadalafil OaD group, one (1.8 %) in the tadala-
fil PRN group, and one (3.1 %) in the placebo group, maintenance of 
improvement could not be calculated because the patients either dis-
continued during DFW or had missing IIEF-EF scores at month 10.5
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were significantly more probable to achieve EF-recovery 
than older patients (p = 0.020; [15]). These results are in 
line with literature.
A 2010 study by Briganti et al. [29] showed that younger 
patients (≤65 years) were more likely to recover EF (IIEF-
EF ≥ 22) than older patients. A meta-analysis by Kilmin-
ster et al. and studies by Nelson et al. and Gallina et al. also 
showed that younger patients were significantly more likely 
to recover EF post-nsRP than older patients [5, 7, 21].
A clear limitation of the current trial was that the 
9-month DBT phase was too short for full assessment of 
EF-recovery. We cannot exclude that the treatment effect of 
tadalafil OaD may be lost by the end of 2 years due to spon-
taneous EF-recovery in the placebo arm. Valid statistical 
analysis of time to EF-recovery could not be performed on 
IIEF-EF data collected after DBT (i.e., after DFW at month 
10.5 or OLT at month 13.5) due to the break in ED treat-
ment for 6 weeks. The significant treatment effect on EF-
recovery was lost during the DFW. However, after 3-month 
OLT with tadalafil OaD (month 13.5), the proportion of 
patients with EF-recovery increased in all treatment groups 
(32.4 % in the tadalafil OaD group; 33.1 % in the tadalafil 
PRN group; and 27.0 % in the placebo group) [15]. Further, 
the results of the Briganti study indicate that the significant 
effect of OaD treatment on time to recovery may persist 
after longer follow-up periods (up to 3 years) [27]. In this 
context, the demonstrated maintenance of tadalafil’s treat-
ment effect could play an important role in future studies 
that allow for longer treatment or follow-up periods. Even 
after DFW, over 75 % of patients treated with tadalafil OaD 
maintained an improvement in ED severity from baseline.
In conclusion, patients taking tadalafil OaD (but not 
those taking PRN) significantly shortened the time to EF-
recovery during DBT when compared with placebo. No 
statistically significant difference in time to EF-recovery 
was observed between younger and older patients. These 
data suggest that tadalafil OaD, if started early, may accel-
erate EF-recovery post-nsRP.
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